Published in Cancer Weekly, October 19th, 2004
"The mechanism of tumor cell killing by OX14503 was investigated by studying vascular functional and morphological changes post drug administration. Severe combined immunodeficient mice bearing MHEC5-T hemangioendothelioma were given a single dose of OX14503 at 100 mg/kg. Tumor blood flow, measured by microsphere fluorescence, was reduced by 50% at 1 hour (h), and reached a maximum level 6-24 h post drug treatments. Tumor vascular permeability, measured by Evan's blue and hemoglobin, increased significantly from 3 hr and peaked at 18 hr," scientists in Sweden report.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.